The molecular epidemiology of Murray Valley encephalitis virus in Australasia

2018 ◽  
Vol 39 (2) ◽  
pp. 106
Author(s):  
David T Williams

Of the viruses transmitted by mosquitoes in the Australasian region, Murray Valley encephalitis (MVE) virus is the major cause of brain disease in humans. There is no vaccine to prevent MVE, nor are there effective antiviral drugs available to treat infections. Therefore, surveillance of MVE is essential to control efforts. A key element to this is understanding the virus at a genetic level, which allows the tracking and identification of known or novel genetic types and can tell us about their circulation patterns.

2015 ◽  
Vol 9 (11) ◽  
pp. e0004240 ◽  
Author(s):  
David T. Williams ◽  
Sinéad M. Diviney ◽  
Aziz-ur-Rahman Niazi ◽  
Peter A. Durr ◽  
Beng Hooi Chua ◽  
...  

2014 ◽  
Vol 2 (3) ◽  
Author(s):  
D. T. Williams ◽  
S. M. Diviney ◽  
K. J. Corscadden ◽  
B. H. Chua ◽  
J. S. Mackenzie

1996 ◽  
Vol 40 (11) ◽  
pp. 847-855 ◽  
Author(s):  
Shao-Ping Ma ◽  
Sakae Arakaki ◽  
Yoshihiro Makino ◽  
Toshihiko Fukunaga

2019 ◽  
Vol 211 (11) ◽  
pp. 499 ◽  
Author(s):  
Leon Caly ◽  
Natalie Davidson ◽  
Ram Ghimire ◽  
Brinthan Rajaratnam ◽  
Jonathan Marrow ◽  
...  

2012 ◽  
Vol 197 (3) ◽  
pp. 150-150 ◽  
Author(s):  
Joseph S Doyle ◽  
Suellen Nicholson ◽  
Jennifer A Leydon ◽  
Rodney J Moran ◽  
Michael G Catton

Author(s):  
David W. Smith ◽  
Annette K. Broom ◽  
John S. Mackenzie

2008 ◽  
Vol 83 (6) ◽  
pp. 2436-2445 ◽  
Author(s):  
Mario Lobigs ◽  
Maximilian Larena ◽  
Mohammed Alsharifi ◽  
Eva Lee ◽  
Megan Pavy

ABSTRACT The Japanese encephalitis virus (JEV) serocomplex, which also includes Murray Valley encephalitis virus (MVEV), is a group of antigenically closely related, mosquito-borne flaviviruses that are responsible for severe encephalitic disease in humans. While vaccines against the prominent members of this serocomplex are available or under development, it is unlikely that they will be produced specifically against those viruses which cause less-frequent disease, such as MVEV. Here we have evaluated the cross-protective values of an inactivated JEV vaccine (JE-VAX) and a live chimeric JEV vaccine (ChimeriVax-JE) against MVEV in two mouse models of flaviviral encephalitis. We show that (i) a three-dose vaccination schedule with JE-VAX provides cross-protective immunity, albeit only partial in the more severe challenge model; (ii) a single dose of ChimeriVax-JE gives complete protection in both challenge models; (iii) the cross-protective immunity elicited with ChimeriVax-JE is durable (≥5 months) and broad (also giving protection against West Nile virus); (iv) humoral and cellular immunities elicited with ChimeriVax-JE contribute to protection against lethal challenge with MVEV; (v) ChimeriVax-JE remains fully attenuated in immunodeficient mice lacking type I and type II interferon responses; and (vi) immunization with JE-VAX, but not ChimeriVax-JE, can prime heterologous infection enhancement in recipients of vaccination on a low-dose schedule, designed to mimic vaccine failure or waning of vaccine-induced immunity. Our results suggest that the live chimeric JEV vaccine will protect against other viruses belonging to the JEV serocomplex, consistent with the observation of cross-protection following live virus infections.


Sign in / Sign up

Export Citation Format

Share Document